enVVeno Medical (NVNO) will present its investigational enVVe System at the annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Diego. Chief Executive Officer Rob Berman is scheduled to deliver the presentation during the Innovation in Endovascular Therapies session on November 2, 2026, at 11:30 a.m. PT. The presentation, titled “Changing the Treatment Paradigm for Deep Venous Disease: Transcatheter Replacement Venous Valve,” will introduce cardiovascular specialists to the system, which is designed to restore one-way blood flow in deep veins.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

YouTube video by Η ΝΑΥΤΕΜΠΟΡΙΚΗ

enVVeno Medical (NASDAQ:NVNO) released the third episode of its investor video series, "WTF with Rob Berman," featuring its CEO.The episode discusses the total addressable market—the potential market size—for severe deep venous insufficiency (DVI). Berman covers the patient population, the market opportunity and what he describes as investors' frequent misunderstandings about market size. The announcement provides no patient-population figures or clinical results.

enVVeno Medical (NVNO) launched a new CEO-led video series, “WTF Rob Berman,” on September 16, 2026, aimed at giving investors direct, plain‑spoken information about the company.Hosted by CEO Rob Berman, the series is intended to move beyond scripted corporate messaging and offer candid, fact‑driven discussion of enVVeno’s technology, clinical programs, regulatory and development progress, upcoming milestones, and corporate decision‑making. Episodes will address topics such as the enVVe® System, the path toward the SAVVE pivotal trial, enVVeno’s venous valve replacement approach, and its strategy toward potential commercialization. The company notes severe deep venous insufficiency (DVI) affects an estimated 3 million people in the U.S. and that the enVVe System is being developed as a potential first‑in‑class bioprosthetic venous valve replacement.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

enVVeno Medical (NASDAQ:NVNO) announced that CEO Robert Berman participated in the Virtual Investor “Why Now” on-demand conference, where he outlined the company’s investment opportunity and the unmet need in treating severe Deep Venous Insufficiency (DVI).Berman discussed enVVeno’s non-surgical replacement venous valve, enVVe, and the recent FDA IDE approval for a U.S. pivotal study of the device. The TAVVE pivotal trial is expected to start in the fourth quarter of 2026 and enroll about 230 patients across up to 40 U.S. sites, as a key step toward potential regulatory approval of the enVVe System. A video webcast of the presentation is available for on-demand viewing. enVVeno is a late clinical-stage medical device company focused on bioprosthetic solutions for deep venous disease.

YouTube video by Somos Radio AM 530 - EN VIVO

In yet another alarming strike on corporate cybersecurity, Nvno has reportedly fallen victim to a coordinated breach orchestrated by the Akira threat group. According to reports from hendryadrian.com and TweetThreatNews, the cyberattack compromised more than 6GB of confidential corporate documents and personal data belonging to over 150 clients. The victims, primarily based in the United States, now face a tangled web of potential identity theft, legal exposure, and financial loss.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.